Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)

Authors

Giulia Cerretti (ORCID: https://orcid.org/0000-0002-2849-0537)
M Corrà
Stefano Indraccolo (ORCID: https://orcid.org/0000-0002-4810-7136)
Gian Luca De Salvo (ORCID: https://orcid.org/0000-0001-7451-8476)
Giuseppe Lombardi
Susanna Mandruzzato (ORCID: https://orcid.org/0000-0002-0707-995X)
Marta Padovan (ORCID: https://orcid.org/0000-0001-7362-3127)
Mario Caccese (ORCID: https://orcid.org/0000-0002-0059-5660)
Renzo Manara (ORCID: https://orcid.org/0000-0002-5130-3971)
Sara Lonardi (ORCID: https://orcid.org/0000-0002-7593-8138)
Maurizio Polano (ORCID: https://orcid.org/0000-0002-6101-1382)
Paola Del Bianco (ORCID: https://orcid.org/0000-0002-6597-0265)
Giovanni Librizzi (ORCID: https://orcid.org/0000-0002-2409-457X)
Alberto Bosio
Marta Maccari

Institutions

University of Padua (IT)
Istituto Oncologico Veneto (IT)
National Cancer Institute (UA)
Istituti di Ricovero e Cura a Carattere Scientifico (IT)

Publication Details

Journal: Trials
Published: 2025-08-04
DOI: https://doi.org/10.1186/s13063-025-08997-2
Primary Topic: Meningioma and schwannoma management
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)

Giulia Cerretti, M Corrà, Stefano Indraccolo, Gian Luca De Salvo et al.

Aug 4, 2025

1 links

Trials

Meningioma and schwannoma management

article

Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study)

Giulia Cerretti, M Corrà, Stefano Indraccolo, Gian Luca De Salvo, Giuseppe Lombardi, Susanna Mandruzzato, Marta Padovan, Mario Caccese, Renzo Manara, Sara Lonardi, Maurizio Polano, Paola Del Bianco, Giovanni Librizzi, Alberto Bosio, Marta Maccari

August 4, 2025article en

Abstract

No abstract available for this paper.

TrialsVol. 26(1)

University of Padua (IT), Istituto Oncologico Veneto (IT), National Cancer Institute (UA), Istituti di Ricovero e Cura a Carattere Scientifico (IT)

Good health and well-being

Openalex Percentile: Top 73%

Meningioma and schwannoma management

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Regorafenib versus local standard of care in patients with grade 2–3 meningioma no longer eligible for loco-regional treatments: a phase II randomized controlled trial (the MIRAGE study) — Giulia Cerretti, M Corrà, et al. · Trials (2025) | TGRS Research Map | TGRS